Small Molecule Immuno-Oncology Compound Library

Description: Immuno-Oncology is a type of immunotherapy that has the specific purpose of treating cancer. It works by stimulating our immune system to fight back. Normally, our immune system is able to destroy cancer cells in our body, however sometimes cancer cells can adapt and mutate, effectively hiding from our immune system. This is when tumors can develop and become a threat to our health. Immuno-oncology involves mobilizing lymphocytes to recognize and eliminate cancer cells using the body’s immune system. There are several immuno-oncology treatments available, including Immune cell therapy (CAR-T), monoclonal antibodies (mABs) and checkpoint inhibitors, cytokines and cancer vaccines.
Immuno-Oncology is a type of immunotherapy that has the specific purpose of treating cancer. It works by stimulating our immune system to fight back. Normally, our immune system is able to destroy cancer cells in our body, however sometimes cancer cells can adapt and mutate, effectively hiding from our immune system. This is when tumors can develop and become a threat to our health. Immuno-oncology involves mobilizing lymphocytes to recognize and eliminate cancer cells using the body’s immune system. There are several immuno-oncology treatments available, including Immune cell therapy (CAR-T), monoclonal antibodies (mABs) and checkpoint inhibitors, cytokines and cancer vaccines.
MCE Small Molecule Immuno-Oncology Compound Library offers 486 bioactive tumor immunology compounds that target some important checkpoints such as PD1/PD-L1, CXCR, Sting, IDO, TLR, etc. This library is a useful tool for Immuno-oncology research.
MCE Small Molecule Immuno-Oncology Compound Library can be supplied as pre-dissolved Solutions or Solid. For pre-dissolved solutions in this library, there are 472 compounds supplied in 10 mM solution, 10 compounds supplied in 2 mM solution and 4 compounds supplied in 3 mg/mL solution.
For pre-dissolved solutions, 10 mM for compounds with the solubility not lower than 10 mM, 2 mM for compounds with solubility between 2 mM and 10 mM, and 3 mg/mL for compounds with unconfirmed molecular weight and solubility not lower than 3 mg/mL.

Advantages:

• A unique collection of 486 bioactive tumor immunology compounds for high throughput screening (HTS) and high content screening (HCS).
• A useful tool for cancer research by activation of an antitumor immune response.
• Small molecule compounds targeting PD1/PD-L1, ROR, CCR, CXCR, Sting, IDO, TLR, etc.
• Bioactivity and safety confirmed by preclinical research and clinical trials, some have been approved by FDA.
• Structurally diverse, medicinally active, and cell permeable.
• More detailed compound information with structure, IC50, and other chemical & biological data.
• NMR and HPLC validated to ensure high purity and quality.
• All compounds are in stock and continuously updated.

Formulation: A collection of 486 bioactive tumor immunology compounds supplied as pre-dissolved Solutions or SolidSolution:472 compounds supplied in 10 mM solution,10 compounds supplied in 2 mM solution,4 compounds supplied in 3 mg/mL solution.

Layout: 96-well storage tube or 96-well plate: 1st and 12th column are left empty.384-well plate: the first two columns and the last two columns are left empty.Compounds with different concentrations or dissolved in different solvents will be put on separate plates.This way of layout may increase the number of plates because there could be three solvents and three concentrations. If you have other requirements, please let us know.

Container: 96- or 384-well Plate with Peelable Foil Seal; 96-well Format Sample Storage Tube With Screw Cap and Optional 2D Barcode

• Artikelnummer: MEXHY-L031-50
• Hersteller: MedChemExpress
• Hersteller Artikelnummer: HY-L031-50
• Green Labware: Nein
• Verpackungseinheit: 50 μl
• Mengeneinheit: STK